Pharmacokinetic drug interactions with clopidogrel: Updated review and risk management in combination therapy

Therapeutics and Clinical Risk Management

Volumn 11, Issue , 2015, Pages 449-467

  Wang, Zhi Yu ^a   Chen, Meng ^a   Zhu, Ling Ling ^b   Yu, Lu Shan ^c   Zeng, Su ^c   Xiang, Mei Xiang ^b   Zhou, Quan ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c ZHEJIANG UNIVERSITY   (China)

Author keywords

Clopidogrel; Drug metabolism; Drug transporter; Drug drug interactions; Genotype; P2Y12< inf> receptor inhibitors; Pharmacogenetics; Pharmacokinetics; Polypharmacy; Risk management

Indexed keywords

ACETYLSALICYLIC ACID; ANTIFUNGAL AGENT; ARYLDIALKYLPHOSPHATASE 1; CALCIUM CHANNEL BLOCKING AGENT; CARBOXYLESTERASE; CERIVASTATIN; CLOPIDOGREL; CURCUMIN; CYCLOSPORIN; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 3A4; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EFAVIRENZ; ESOMEPRAZOLE; FERULIC ACID; FLUOXETINE; HYPERICUM PERFORATUM EXTRACT; MORPHINE; MULTIDRUG RESISTANCE PROTEIN; OMEPRAZOLE; REPAGLINIDE; RIFAMPICIN; RITONAVIR; SCUTELLARIN; SIBUTRAMINE; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1; SULFONYLUREA DERIVATIVE; UNINDEXED DRUG;

AREA UNDER THE CURVE; CARDIOVASCULAR DISEASE; COMBINATION CHEMOTHERAPY; DEPRESSION; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG INHIBITION; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; FOOD DRUG INTERACTION; GENETIC POLYMORPHISM; GRAPEFRUIT JUICE; HEREDITY; HUMAN; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; OUTCOME ASSESSMENT; PAIN; REVIEW; RISK MANAGEMENT; SMOKING; SPECIES DIFFERENCE;

EID: 84928103055     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/TCRM.S80437     Document Type: Review

References (97)

1. Li W, Zeng S, Yu LS, Zhou Q. Pharmacokinetic drug interaction profle of omeprazole with adverse consequences and clinical risk management. Ther Clin Risk Manag. 2013;9:259–271.
2. Zhou YT, Yu LS, Zeng S, Huang YW, Xu HM, Zhou Q. Pharmacokinetic drug–drug interactions between 1,4-dihydropyridine calcium channel blockers and statins: factors determining interaction strength and relevant clinical risk management. Ther Clin Risk Manag. 2014;10:17–25.
3. Joint Commission International. Accreditation Standards for Hospitals. 5th ed. Oak Brook, IL, USA: Joint Commission Resources; 2013.
4. Wikipedia. Clopidogrel. Available from: http://en.wikipedia.org/wiki/Clopidogrel. Accessed January 2, 2014.
5. Kounis NG, Grapsas N. Pathways of platelet activation and unexplained clopidogel variability: causes of poor response to clopidogrel. Thromb Res. 2013;132:312.
6. Ferri N, Corsini A, Bellosta S. Pharmacology of the new P2Y12 receptor inhibitors: insights on pharmacokinetic and pharmacodynamic properties. Drugs. 2013;73:1681–1709.
7. Egan G, Hughes CA, Ackman ML. Drug interactions between anti-platelet or novel oral anticoagulant medications and antiretroviral medications. Ann Pharmacother. 2014;48:734–740.
8. Shah BS, Parmar SA, Mahajan S, Mehta AA. An insight into the interaction between clopidogrel and proton pump inhibitors. Curr Drug Metab. 2012;13:225–235.
9. Scott SA, Owusu Obeng A, Hulot JS. Antiplatelet drug interactions with proton pump inhibitors. Expert Opin Drug Metab Toxicol. 2014; 10:175–189.
10. Siller-Matula JM, Trenk D, Krähenbühl S, Michelson AD, Delle-Karth G. Clinical implications of drug–drug interactions with P2Y12 receptor inhibitors. J Thromb Haemost. 2014;12:2–13.
11. Tabassome S, Celine V, Murielle MK, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009; 360:363–375.
12. Kazui M, Nishiya Y, Ishizuka T, et al. Identifcation of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos. 2010;38:92–99.
13. Fareed J, Jeske W, Thethi I. Metabolic differences of current thienopyri-dine antiplatelet agents. Expert Opin Drug Metab Toxicol. 2013; 9:307–317.
14. Floyd JS, Kaspera R, Marciante KD, et al. A screening study of drug– drug interactions in cerivastatin users: an adverse effect of clopidogrel. Clin Pharmacol Ther. 2012;91:896–904.
15. Tornio A, Filppula AM, Kailari O, et al. Glucuronidation converts clopidogrel to a strong time-dependent inhibitor of CYP2C8: a phase II metabolite as a perpetrator of drug–drug interactions. Clin Pharmacol Ther. 2014;96:498–507.
16. Tamraz B, Fukushima H, Wolfe AR, et al. OATP1B1-related drug–drug and drug-gene interactions as potential risk factors for cerivastatin-in-duced rhabdomyolysis. Pharmacogenet Genomics. 2013;23:355–364.
17. Schmidt M, Johansen MB, Maeng M, et al. Concomitant use of clopi-dogrel and statins and risk of major adverse cardiovascular events following coronary stent implantation. Br J Clin Pharmacol. 2012;74: 161–170.
18. Farid NA, Small DS, Payne CD, et al. Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects. Pharmacotherapy. 2008;28:1483–1494.
19. Ayalasomayajula SP, Vaidyanathan S, Kemp C, Prasad P, Balch A, Dole WP. Effect of clopidogrel on the steady-state pharmacokinetics of fuvastatin. J Clin Pharmacol. 2007;47:613–619.
20. Pinheiro LF, França CN, Izar MC, et al. Pharmacokinetic interactions between clopidogrel and rosuvastatin: effects on vascular protection in subjects with coronary heart disease. Int J Cardiol. 2012;158:125–129.
21. Teng R, Mitchell PD, Butler KA. Pharmacokinetic interaction studies of co-administration of ticagrelor and atorvastatin or simvastatin in healthy volunteers. Eur J Clin Pharmacol. 2013;69:477–487.
22. Scheen AJ. Drug–drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide. Clin Pharma-cokinet. 2007;46:93–108.
23. Yu L, Lu S, Lin Y, Zeng S. Carboxyl-glucuronidation of mitiglinide by human UDP-glucuronosyltransferases. Biochem Pharmacol. 2007; 73:1842–1851.
24. Zhou D, Andersson TB, Grimm S W. In vitro evaluation of potential drug–drug interactions with ticagrelor: cytochrome P450 reaction phe-notyping, inhibition, induction, and differential kinetics. Drug Metab Dispos. 2011;39:703–710.
25. Li Y, Liu C, Zhang Y, Mi S, Wang N. Pharmacokinetics of ferulic acid and potential interactions with Honghua and clopidogrel in rats. J Ethnopharmacol. 2011;137:562–567.
26. Bae SK, Cao S, Seo KA, et al. Cytochrome P450 2B6 catalyzes the formation of pharmacologically active sibutramine (N-{1-[1-(4-chloro-phenyl)cyclobutyl]-3-methylbutyl}-N,N-dimethylamine) metabolites in human liver microsomes. Drug Metab Dispos. 2008;36:1679–1688.
27. Nishiya Y, Hagihara K, Kurihara A, et al. Comparison of mechanism-based inhibition of human cytochrome P450 2C19 by ticlopidine, clopidogrel, and prasugrel. Xenobiotica. 2009;39:836–843.
28. Bae JW, Jang CG, Lee SY. Effects of clopidogrel on the pharmacokinet-ics of sibutramine and its active metabolites. J Clin Pharmacol. 2011; 51:1704–1711.
29. Pan W, Bae SK, Shim EJ, et al. Effects of clopidogrel and clarithromycin on the disposition of sibutramine and its active metabolites M1 and M2 in relation to CYP2B6*6 polymorphism. Xenobiotica. 2013;43:211–218.
30. Peeters PA, Crijns HJ, Tamminga WJ, Jonkman JH, Dickinson JP, Necciari J. Clopidogrel, a novel antiplatelet agent, and digoxin: absence of pharmacodynamic and pharmacokinetic interaction. Semin Thromb Hemost. 1999;25 Suppl 2:51–54.
31. Teng R, Butler K. A pharmacokinetic interaction study of ticagrelor and digoxin in healthy volunteers. Eur J Clin Pharmacol. 2013; 69:1801–1808.
32. RxList®. BRILINTA® (ticagrelor) tablets. New York, NY, USA. Available from: http://www.rxlist.com/brilinta-drug/clinical-pharmacology.htm. Accessed January 1, 2014.
33. Abdelhady AM, Desta Z, Jiang F, Ye o CW, Shin JG, Overholser BR. Population pharmacogenetic-based pharmacokinetic modeling of efa-virenz, 7-hydroxy- and 8-hydroxyefavirenz. J Clin Pharmacol. 2014; 54:87–96.
34. Jiang F, Desta Z, Shon JH, et al. Effects of clopidogrel and itraconazole on the disposition of efavirenz and its hydroxyl metabolites: exploration of a novel CYP2B6 phenotyping index. Br J Clin Pharmacol. 2013;75:244–253.
35. Xu C, Ogburn ET, Guo Y, Desta Z. Effects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo. Drug Metab Dispos. 2012;40:717–725.
36. Chen BL, Chen Y, Tu JH, et al. Clopidogrel inhibits CYP2C19-dependent hydroxylation of omeprazole related to CYP2C19 genetic polymorphisms. J Clin Pharmacol. 2009;49:574–581.
37. Angiolillo DJ, Gibson CM, Cheng S, et al. Differential effects of omepra-zole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin Pharmacol Ther. 2011;89:65–74.
38. Frelinger AL 3rd, Lee RD, Mulford DJ, et al. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lanso-prazole, esomeprazole, and omeprazole on the steady-state pharma-cokinetics and pharmacodynamics of clopidogrel in healthy volunteers. J Am Coll Cardiol. 2012;59:1304–1311.
39. Johnson DA, Chilton R, Liker HR. Proton-pump inhibitors in patients requiring antiplatelet therapy: new FDA labeling. Postgrad Med. 2014; 126:239–245.
40. Harmsze AM, van Werkum JW, Taubert D, Hackeng CM, Deneer VH. Esomeprazole but not pantoprazole is associated with lower plasma concentrations of clopidogrel’s active metabolite. Ann Pharmacother. 2011;45:542–543.
41. Funck-Brentano C, Szymezak J, Steichen O, et al. Effects of rabepra-zole on the antiplatelet effects and pharmacokinetics of clopidogrel in healthy volunteers. Arch Cardiovasc Dis. 2013;106:661–671.
42. Wu J, Jia LT, Shao LM, et al. Drug–drug interaction of rabeprazole and clopidogrel in healthy Chinese volunteers. Eur J Clin Pharmacol. 2013;69:179–187.
43. Ferreiro JL, Ueno M, Capodanno D, et al. Pharmacodynamic effects of concomitant versus staggered clopidogrel and omeprazole intake: results of a prospective randomized crossover study. Circ Cardiovasc Interv. 2010;3:436–441.
44. Moceri P, Doyen D, Cerboni P, Ferrari E. Doubling the dose of clopi-dogrel restores the loss of antiplatelet effect induced by esomeprazole. Thromb Res. 2011;128:458–462.
45. Collet JP, Hulot JS, Abtan J, et al. Prasugrel but not high dose clopi-dogrel overcomes the lansoprazole neutralizing effect of P2Y12 inhibition: results of the randomized DOSAPI study. Eur J Clin Pharmacol. 2014;70:1049–1057.
46. Small DS, Farid NA, Li YG, et al. Effect of ranitidine on the pharma-cokinetics and pharmacodynamics of prasugrel and clopidogrel. Curr Med Res Opin. 2008;24:2251–2257.
47. Ohbuchi M, Noguchi K, Kawamura A, Usui T. Different effects of proton pump inhibitors and famotidine on the clopidogrel metabolic activation by recombinant CYP2B6, CYP2C19 and CYP3A4. Xeno-biotica. 2012;42:633–640.
48. Small DS, Farid NA, Payne CD, et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol. 2008;48:475–484.
49. Hobl EL, Stimpf T, Ebner J, et al. Morphine decreases clopidogrel concentrations and effects: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 2014;63:630–635.
50. Parodi G, Valenti R, Bellandi B, et al. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. J Am Coll Cardiol. 2013;61:1601–1606.
51. Chen X, Jin J, Chen Y, et al. Effect of scutellarin on the metabolism and pharmacokinetics of clopidogrel in rats. Biopharm Drug Dispos. 2015;36:64–68.
52. Delavenne X, Magnin M, Basset T, et al. Investigation of drug–drug interactions between clopidogrel and fuoxetine. Fundam Clin Pharmacol. 2013;27:683–689.
53. Teng R, Kujacic M, Hsia J. Evaluation of the pharmacokinetic interaction between ticagrelor and venlafaxine, a cytochrome P-450 2D6 substrate, in healthy subjects. Clin Ther. 2014;36:1217–1225.
54. Oganesian A, Shilling AD, Young-Sciame R, et al. Desvenlafaxine and venlafaxine exert minimal in vitro inhibition of human cyto-chrome P450 and P-glycoprotein activities. Psychopharmacol Bull. 2009;42:47–63.
55. Farid NA, Payne CD, Small DS, et al. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacoki-netics and pharmacodynamics differently. Clin Pharmacol Ther. 2007;81:735–741.
56. Suh JW, Koo BK, Zhang SY, et al. Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel. CMAJ. 2006;174:1715–1722.
57. Harmsze AM, Robijns K, van Werkum JW, et al. The use of amlo-dipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor response. Thromb Haemost. 2010; 103:920–925.
58. Seo KD, Kim YD, Yoon YW, Kim JY, Lee K Y. Antiplatelet effect of clopidogrel can be reduced by calcium channel blockers. Yonsei Med J. 2014;55:683–688.
59. Park JJ, Park KW, Kang J, et al. CYP3A4 genetic status may be associated with increased vulnerability to the inhibitory effect of calcium-channel blockers on clopidogrel. Circ J. 2013;77:1289–1296.
60. Harmsze AM, Van Werkum JW, Moral F, et al. Sulfonylureas and on-clopidogrel platelet reactivity in type 2 diabetes mellitus patients. Platelets. 2011;22:98–102.
61. Harmsze AM, van Werkum JW, Bouman HJ, et al. Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation. Pharmacogenet Genomics. 2010; 20:18–25.
62. Teng R, Mitchell P, Butler K. Evaluation of the pharmacokinetic interaction between ticagrelor and tolbutamide, a cytochrome P450 2C9 substrate, in healthy volunteers. Int J Clin Pharmacol Ther. 2013;51: 305–312.
63. Metzger NL, Momary KM. A patient with HIV and tuberculosis with diminished clopidogrel response. Int J STD AIDS. 2013;25:532–534.
64. Ancrenaz V, Déglon J, Samer C, et al. Pharmacokinetic interaction between prasugrel and ritonavir in healthy volunteers. Basic Clin Pharmacol Toxicol. 2013;112:132–137.
65. Daali Y, Ancrenaz V, Bosilkovska M, Dayer P, Desmeules J. Ritonavir inhibits the two main prasugrel bioactivation pathways in vitro: a potential drug–drug interaction in HIV patients. Metabolism. 2011;60: 1584–1589.
66. Jung KH, Chu K, Lee ST, et al. Prolonged use of aspirin alters human and rat intestinal cells and thereby limits the absorption of clopidogrel. Clin Pharmacol Ther. 2011;90:612–619.
67. Oh J, Shin D, Lim KS, et al. Aspirin decreases systemic exposure to clopidogrel through modulation of P-glycoprotein but does not alter its antithrombotic activity. Clin Pharmacol Ther. 2014;95:608–616.
68. Liang Y, Hirsh J, Weitz JI, et al. Active metabolite concentration of clopidogrel in patients taking different doses of aspirin: results of the Interaction Trial. J Thromb Haemost. December 30, 2014. [Epub ahead of print].
69. Taubert D, von Beckerath N, Grimberg G, et al. Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther. 2006;80:486–501.
70. Chen XP, Tan ZR, Huang SL, Huang Z, Ou-Yang DS, Zhou HH. Isozyme-specifc induction of low-dose aspirin on cytochrome P450 in healthy subjects. Clin Pharmacol Ther. 2003;73:264–271.
71. Bouman HJL, Schömig E, van Werkum JW, et al. Paraoxonase-1 is a major determinant of clopidogrel effcacy. Nat Med. 2011;17: 110–116.
72. Jaichander P, Selvarajan K, Garelnabi M, Parthasarathy S. Induction of paraoxonase 1 and apolipoprotein A-I gene expression by aspirin. J Lipid Res. 2008;49:2142–2148.
73. Liu AC, Zhao LX, Lou HX. Curcumin alters the pharmacokinetics of warfarin and clopidogrel in Wistar rats but has no effect on anticoagula-tion or antiplatelet aggregation. Planta Med. 2013;79:971–977.
74. He X, Mo L, Li ZY, Tan ZR, Chen Y, Ouyang DS. Effects of curcumin on the pharmacokinetics of talinolol in human with ABCB1 polymorphism. Xenobiotica. 2012;42:1248–1254.
75. Trana C, Toth G, Wijns W, Barbato E. Clopidogrel undergoing percutaneous coronary intervention: a single-center randomized open-label trial (St John’s Trial). J Cardiovasc Transl Res. 2013;6:411–414.
76. Lau WC, Welch TD, Shields T, Rubenfre M, Tantry US, Gurbel PA. The effect of St John’s wort on the pharmacodynamic response of clopidogrel in hyporesponsive volunteers and patients: increased platelet inhibition by enhancement of CYP3A4 metabolic activity. J Cardiovasc Pharmacol. 2011;57:86–93.
77. Lee JH, Shin YJ, Kim HJ, Oh JH, Jang YP, Lee YJ. Danshen extract does not alter pharmacokinetics of docetaxel and clopidogrel, refecting its negligible potential in P-glycoprotein- and cytochrome P4503A-mediated herb-drug interactions. Int J Pharm. 2011;410:68–74.
78. Lee JH, Shin YJ, Oh JH, Lee YJ. Pharmacokinetic interactions of clopidogrel with quercetin, telmisartan, and cyclosporine A in rats and dogs. Arch Pharm Res. 2012;35:1831–1837.
79. Teng R, Kujacic M, Hsia J. Pharmacokinetic interaction study of ticagrelor and cyclosporine in healthy volunteers. Clin Drug Investig. 2014;34:529–536.
80. Judge HM, Patil SB, Buckland RJ, Jakubowski JA, Storey RF. Potentia-tion of clopidogrel active metabolite formation by rifampicin leads to greater P2Y12 receptor blockade and inhibition of platelet aggregation after clopidogrel. J Thromb Haemost. 2010;8:1820–1827.
81. Teng R, Mitchell P, Butler K. Effect of rifampicin on the pharmacoki-netics and pharmacodynamics of ticagrelor in healthy subjects. Eur J Clin Pharmacol. 2013;69:877–883.
82. Farid NA, Jakubowski JA, Payne CD, et al. Effect of rifampin on the pharmacokinetics and pharmacodynamics of prasugrel in healthy male subjects. Curr Med Res Opin. 2009;25:1821–1829.
83. Kristensen KE, Zhu HJ, Wang X, et al. Clopidogrel bioactivation and risk of bleeding in patients cotreated with angiotensin-converting enzyme inhibitors after myocardial infarction: a proof-of-concept study. Clin Pharmacol Ther. 2014;96:713–722.
84. Yousef AM, Arafat T, Bulatova NR, et al. Smoking behaviour modulates pharmacokinetics of orally administered clopidogrel. J Clin Pharm Ther. 2008;33:439–449.
85. Hochholzer W, Trenk D, Mega JL, et al. Impact of smoking on anti-platelet effect of clopidogrel and prasugrel after loading dose and on maintenance therapy. Am Heart J. 2011;162:518–526.
86. Park KW, Park JJ, Jeon KH, et al. Enhanced clopidogrel responsiveness in smokers: smokers’ paradox is dependent on cytochrome P450 CYP1A2 status. Arterioscler Thromb Vasc Biol. 2011;31:665–671.
87. Gurbel PA, Bliden KP, Logan DK, et al. The infuence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and pra-sugrel: the PARADOX study. J Am Coll Cardiol. 2013;62:505–512.
88. Caplain H, Thebault JJ, Necciari J. Clopidogrel does not affect the pharmacokinetics of theophylline. Semin Thromb Hemost. 1999; 25 Suppl 2:65–68.
89. Nirogi RV, Kandikere VN, Mudigonda K. Effect of food on bioavail-ability of a single oral dose of clopidogrel in healthy male subjects. Arzneimittelforschung. 2006;56:735–739.
90. Hurbin F, Boulenc X, Daskalakis N, et al. Clopidogrel pharmacodynam-ics and pharmacokinetics in the fed and fasted state: a randomized crossover study of healthy men. J Clin Pharmacol. 2012;52:1506–1515.
91. Teng R, Mitchell PD, Butler K. Lack of signifcant food effect on the pharmacokinetics of ticagrelor in healthy volunteers. J Clin Pharm Ther. 2012;37:464–468.
92. Small DS, Farid NA, Payne CD, et al. Effect of intrinsic and extrinsic factors on the clinical pharmacokinetics and pharmacodynamics of prasugrel. Clin Pharmacokinet. 2010;49:777–798.
93. Holmberg MT, Tornio A, Neuvonen M, Neuvonen PJ, Backman JT, Niemi M. Grapefruit juice inhibits the metabolic activation of clopi-dogrel. Clin Pharmacol Ther. 2014;95:307–313.
94. Holmberg MT, Tornio A, Joutsi-Korhonen L, et al. Grapefruit juice markedly increases the plasma concentrations and antiplatelet effects of ticagre-lor in healthy subjects. Br J Clin Pharmacol. 2013;75:1488–1496.
95. Campbell KL, Cohn JR, Fischman DL, et al. Management of clopidogrel hypersensitivity without drug interruption. Am J Cardiol. 2011;107: 812–816.
96. Karabay CY, Can MM, Tanboğa IH, Ahmet G, Bitigen A, Serebruany V. Recurrent acute stent thrombosis due to allergic reaction secondary to clopidogrel therapy. Am J Ther. 2011;18:e119–e122.
97. Kounis NG, Soufras GD. Coronary stent thrombosis: beware of an allergic reaction and of Kounis syndrome. Indian Heart J. 2014; 66:153–155.